SAN DIEGO, Jan. 23 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. announced today that key data from Thiovir(TM) preclinical studies will be presented at the HIV Pathogenesis Meeting, in Keystone, Colorado, which takes place March 27 - April 2, 2006. The abstract entitled “Synergistic Antiviral Activity and Additive Cytotoxicity of Thiovir Combined with Zidovudine” is scheduled for presentation on Friday, March 31. Thiovir is a non-nucleoside reverse transcriptase inhibitor (NNRTI) designed for oral delivery as a component of AZT-based highly active antiretroviral therapy (HAART) for HIV/AIDS.
“We look forward to presenting these additional results from our extensive preclinical synergy studies using Thiovir in conjunction with AZT,” said Evan M. Levine, ADVENTRX president and CEO. “We believe these and other recent preclinical studies are convincing evidence in favor of our clinical strategy for Thiovir in treatment-experienced HIV/AIDS patients. An investigational new drug application is in progress and planned to be filed with the FDA during the first half of 2006.”
About Thiovir
Thiovir is a non-nucleoside reverse transcriptase inhibitor (NNRTI) designed for oral delivery as a component of AZT-based highly active antiretroviral therapy (HAART). Thiovir is a prodrug for foscarnet that delivers both the active drug TPFA (thiophosphonoformate) and the active metabolite PFA (foscarnet) in an oral formulation. Thiovir is intended to deliver the benefits of the drug foscarnet, including broad spectrum antiviral activity, with the added benefit of improved cell permeability. ADVENTRX currently plans to file an investigational new drug application with the US Food and Drug Administration in the first half of 2006.
About ADVENTRX
ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on introducing new technologies for anticancer and antiviral treatments that surpass the performance and safety of existing drugs, by addressing significant problems such as drug metabolism, toxicity, bioavailability and resistance. More information can be found on the Company’s Web site at www.adventrx.com.
Forward Looking Statement
This press release contains forward-looking statements, within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, regarding ADVENTRX. Such statements are made based on management’s current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the FDA and other regulatory agencies. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements regarding ADVENTRX, see the section titled “Risk Factors” in ADVENTRX’s last quarterly report on Form 10-Q, as well as other reports that ADVENTRX files from time to time with the Securities and Exchange Commission. All forward-looking statements regarding ADVENTRX are qualified in their entirety by this cautionary statement. ADVENTRX undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof.
ADVENTRX Pharmaceuticals, Inc.
CONTACT: Andrea Lynn of ADVENTRX Pharmaceuticals, Inc., +1-858-552-0866
Web site: http://www.adventrx.com/
Company News On-Call: http://www.prnewswire.com/comp/920134.html /
